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MADR2 Maps to 18q21 and Encodes a
TGFb–Regulated MAD–Related Protein
That Is Functionally Mutated
in Colorectal Carcinoma
Kolja Eppert,6,5 Stephen W. Scherer,2 carcinoma and melanoma cell lines have demonstrated
a progressive loss of responsiveness to TGFb growth-Hilmi Ozcelik,3 Rosa Pirone,1
Pamela Hoodless,1 Hyeja Kim,5 inhibitory effects astumor aggressiveness increases (re-
viewed by Filmus and Kerbel, 1993; Roberts and Sporn,Lap-Chee Tsui,6,2 Bharati Bapat,3
Steven Gallinger,5,4 Irene L. Andrulis,6,5,3,8 1993). Thus, an understanding of the molecular events
Gerald H. Thomsen,9 Jeffrey L. Wrana,1 associated with loss of TGFb responsiveness in tumors
and Liliana Attisano7,1 could provide major insights into the general mecha-
1Program in Developmental Biology nisms underlying the development of malignancies. At
Division of Gastroenterology present, the mechanism for the escape from TGFb regu-
2Department of Genetics lation is not clear; however, mutational inactivation of
The Hospital for Sick Children components of TGFb signaling pathways could be one
555 University Avenue mechanism underlying acquisition of TGFb resistance.
Toronto, Ontario TGFb signals through heteromeric receptor com-
Canada M5G 1X8 plexes of type I (TbR I) and type II (TbR II) serine/threo-
3Department of Pathology and Laboratory Medicine nine kinase receptors (reviewed by Massague´ et al.,
4Department of Surgery 1994; Miyazono et al., 1994). Receptor activation occurs
5Samuel Lunenfeld Research Institute upon binding of ligand to TbR II, which then recruits and
Mount Sinai Hospital phosphorylates TbR I, which propagates the signal to
Toronto, Ontario downstream targets (Chen and Weinberg, 1995; Wrana
Canada M5G 1X8 et al., 1994). A pivotal role for the type I receptor in prop-
6Department of Molecular and Medical Genetics gating signals is supported by the observation that con-
7Department of Anatomy and Cell Biology stitutively active type I receptorsare capable of signaling
8Department of Cellular and Molecular Pathology biological responses in the absence of both ligand and
University of Toronto type II receptors (Attisano et al., 1996; Hoodless et al.,
Toronto, Ontario 1996; Nellen et al., 1996; Wieser et al., 1995). Consistent
Canada M5S 1A8 with this, the specificity of cellular responses to TGFb
9Department of Biochemistry and Cell Biology superfamily members also appears to be mediated by
Institute for Cell and Developmental Biology the type I receptors. Thus, TGFb and activin signal simi-
State University of New York lar antiproliferative and gene responses through their
Stony Brook, New York 11794-5215 highly related type I receptors (Ca´rcamo et al., 1994).
Several studies have indicated that alterations in
TGFb receptor expression or function may be involved
Summary in some cancers. For example, in a subset of colon
cancer cell lines that display high rates of microsatellite
The MAD–related (MADR) family of proteins are essen- instability and in several TGFb–resistant human gastric
tial components in the signaling pathways of serine/ cancers, genetic changes in the type II receptor have
threonine kinase receptors for the transforming been identified (Markowitz et al., 1995; Park et al., 1994).
growth factor b (TGFb) superfamily. We demonstrate However, since intracellular targets of the TGFb recep-
that MADR2 is specifically regulated by TGFb and not tors are poorly understood, the importance of disrupting
bone morphogenetic proteins. The gene for MADR2 TGFb signaling pathways in promoting tumorigenesis is
was found to reside on chromosome 18q21, near unknown.
DPC4, another MADR protein implicated in pancreatic Recently, MADs (mothers against dpp) and MADR
cancer. Mutational analysis of MADR2 in sporadic tu- (MAD–related) proteins have been identified in a variety
mors identified four missense mutations in colorectal of species as important components of the signal trans-
carcinomas, two of which display a loss of heterozy- duction pathway that are required for serine/threonine
gosity. Biochemical and functional analysis of three kinase receptor signaling (Graff et al., 1996; Hoodless
of these demonstrates that the mutations are inacti- et al., 1996; Liu et al., 1996; Newfeld et al., 1996; Savage
vating. These findings suggest that MADR2 is a tumor et al., 1996; Sekelsky et al., 1995; Thomsen, 1996; Wiers-
suppressor and that mutations acquired in colorectal dorff et al., 1996). Drosophila MAD and the highly related
carcinomas may function to disrupt TGFb signaling. vertebrate MADR1 appear to be essential for signaling
of DPP/BMP2 pathways and can specify bone morpho-
Introduction genetic protein (BMP)–specific biological responses
(Graff et al., 1996; Hoodless et al., 1996; Newfeld et
al., 1996; Thomsen, 1996; Wiersdorff et al., 1996). MADAn important step in the development of malignant tu-
mors may involve the loss of sensitivity to negative proteins, although highly conserved across species, do
not contain any known structural motifs; thus, it is diffi-growth regulators. TGFb, a potent natural antiprolifera-
tive agent, is believed to play an important role in sup- cult to predict their precise mode of action (reviewed by
Massague´, 1996; Wrana and Attisano, 1996). However,pressing tumorigenicity. Comparisons of human colon
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Figure 1. Sequence Comparison of Mamma-
lian MAD–Related Proteins
Alignment of the predicted amino acid se-
quences of human MADR1, MADR2, and
DPC4. Residues conserved in all three se-
quences are boxed, and the MH1 and MH2
regions at the amino- and carboxyl-termini
are indicated (MH1, solid overline; MH2, bro-
ken overline). Gaps introduced to maximize
alignment are shown as dots, and the amino
acid residues are numbered on the right.
MADR1 is rapidly and specifically phosphorylated by database of expressed sequence tags (Lennon et al.,
1996). A pair of nonoverlapping partial clones were iden-BMP2 and not TGFb–induced pathways (Hoodless et
al., 1996). Furthermore, MADR1 redistributes from the tified that contained open reading frames that displayed
similarity either to the amino- or the carboxyl-terminuscytoplasm to the nucleus upon induction of signaling,
suggesting that MADs may have a nuclear function of MADR1. To obtain the full-length coding sequence,
we designed primers encoding the predicted start and(Hoodless et al., 1996; Liu et al., 1996) and may act as
transcriptional activators (Liu et al., 1996). Recently, a stop codons for polymerase chain reaction (PCR) and
used a human kidney cDNA library as template. A contig-search for tumor suppressor genes implicated in pan-
creatic cancer led to the identification of the MAD– uous sequence of 1605 base pairs was obtained, which
included an open reading frame of 467 amino acidsrelated gene, DPC4 (Hahn et al., 1996a). However, the
signaling pathway in which DPC4 functions is unknown. (Figure 1). The predicted protein is related to MAD and
MADR1, and, thus, we have termed this protein MADR2.In this study, we demonstrate that MADR2 is rapidly
phosphorylated by activation of TGFb signaling path- An alignment of MADR2 with the other mammalian
MAD–related molecules indicates that it is more closelyways. The gene for MADR2 maps close to DPC4 at
18q21, a region often deleted in human cancers (Vo- related to MADR1 than to DPC4, a candidate tumor
suppressor gene in pancreatic cancer (Hahn et al.,gelstein et al., 1988; Yamaguchi et al., 1992). Analysis of
MADR2 in sporadic colorectal carcinoma has identified 1996a). Further, MADR2 is highly related (98% identity)
to the Xenopus homolog, XMad2 (data not shown; Grafffour missense mutations in MADR2, two of which are
associated with a loss of heterozygosity (LOH). Bio- et al., 1996). As described for MADR1, the highest de-
gree of conservation between MADR2 and the otherchemical analysis indicates that three of these missense
mutations lead to either a loss of protein expression or MADs lies in the MH1 and MH2 domains (Figure 1).
loss of TGFb–regulated phosphorylation. Furthermore,
functional analysis of mesoderm induction in Xenopus Phosphorylation of MADR2 by TGFb
Signaling Pathwaysembryos demonstrates that these three mutations also
lead to inactive protein. Thus, MADR2, a component of Since MADR1 functions in BMP2 signaling pathways
and is regulated by phosphorylation (Hoodless et al.,the TGFb signaling pathway, is functionally mutated in
tumors and is implicated as a tumor suppressor gene 1996), we sought to determine which serine/threonine
kinase receptor–activated pathways might regulatein colorectal carcinoma. Together with the suggested
involvement of DPC4 in pancreatic cancer, these find- MADR2. To examine this, we utilized constitutively ac-
tive type I serine/threonine kinase receptors. These typeings indicate that MADs may represent a new class of
tumor suppressor genes important in human cancer. I receptors, generated by the introduction of a charged
residue in the highly conserved GS domain (Attisano et
al., 1996; Hoodless et al., 1996; Wieser et al., 1995),Results
signal in the absence of ligand and type II receptors
(Wieser et al., 1995). To facilitate our analysis, we con-Identification of a MAD–Related Protein, MADR2
MAD and MAD–related proteins identified in Drosophila structed a mammalian expression vector that encoded
a Flag epitope tag at the amino-terminus of MADR2(MAD), Caenorhabditis elegans (sma-2, sma-3, sma-4),
Xenopus (Xmad1 and Xmad2), and humans (MADR1, (FlagMADR2). To explore whether MADR2 was a target
of TGFb or BMP signaling pathways, COS cells wereDPC4) have been demonstrated to play a crucial role in
signal transduction by members of the TGFb superfam- transiently transfected with FlagMADR2 alone or to-
gether with wild-type or activated TbRI or ALK-3 (a BMPily (reviewed by Massague´, 1996; Wrana and Attisano,
1996). Toclone a MAD–related molecule that might func- type I receptor). FlagMADR2 was isolated by immuno-
precipitation from [32P]phosphate-labeled transfectants.tion specifically in the TGFb pathway, we searched a
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TGFb for 15 min revealed a ligand-dependent phosphor-
ylation in both pools (Figure 2). Thus, brief treatment of
epithelial cells with TGFb induces phosphorylation of
MADR2.
Together, these data indicate that MADR2 is regulated
by the TGFb and not BMP receptor signaling pathways
and, along with the known function of MAD proteins
in serine/threonine kinase receptor signal transduction,
suggest that MADR2 plays a role in mediating TGFb
signals.
Regional Localization of MADR2 to Chromosome
18q21 Near DPC4 and DCC
The involvement of MADR2 in the TGFb signaling path-
way suggested that this gene might function as a tumor
suppressor. To investigate this possibility, we deter-Figure 2. MADR2 Phosphorylation Is Induced by TGFb
mined the chromosomal localization of MADR2 using a(A) Regulation of MADR2 phosphorylation by constitutively active
type I receptors in COS-1 cells. COS-1 cells were transiently combination of radiation hybrid (RH) mapping, yeast
transfected with empty vector (pCMV5), FlagMADR2 alone, or Flag- artificial chromosome (YAC) contig analysis, and fluo-
MADR2 with the indicated wild type (WT) or constitutively active (A) rescence in situ hybridization. PCR primers designed
type I receptors. Transfected cells were labeled with [32P]phosphate,
from the 39-UTR of MADR2 were initially used to screenand FlagMADR2 was purified from cell lysates by immunoprecipita-
the GeneBridge 4 RH panel (Walter et al., 1994), and thetion using anti-Flag antibodies and analyzed by SDS–PAGE and
results indicated that the gene resides on chromosomeautoradiography (32PO4). Total MADR2 protein was determined by
immunoblotting total cell lysates obtained from unlabeled cultures 18q21 approximately 9.3 cR from D18S460. The same
that were prepared in parallel using anti-Flag monoclonal antibody primers were also used toscreen the Centre d’Etudes du
(a-Flag blot). The migration of MADR2 is indicated on the left. Polymorphisme Humain megaYAC library (Chumakov et
(B) TGFb–dependent phosphorylation in Mv1Lu epithelial cells.
al., 1995), and five YACs (739a3, 749d11, 887e9, 929d7,Mv1Lu cells were stably transfected with empty vector (pMEP4) or
940e10) were identified. These clones have been shownwith FlagMADR2 under the control of a metallothionein-inducible
previously by the Whitehead Institute–MIT Center forpromoter and two independent pools isolated. Cells were induced
overnight with 50 mM Zn21, labeled with [32P]phosphate in the ab- Genome Research to map within a well-defined YAC
sence (2) or presence (1) of 100 pM TGFb for 15 min and MADR2 contig on chromosome 18 (the contig was named
phosphorylation analyzed as described in (A). The migration of WC18.5). This contig encompasses the same DNA
MADR2 is indicated on the right. marker, D18S460, which we linked to MADR2 on the RH
map (Hudson et al., 1995), and further analysis of our
YACs identified three clones that contained bothAnalysis of the immunoprecipitates revealed that phos-
phorylation of MADR2 was unaffected by the coexpres- MADR2 and D18S460 (Figure 3). The cytogenetic posi-
tion of MADR2 was confirmed further by fluorescencesion of wild-type TbRI, wild-type ALK-3, or activated
ALK-3 (Figure 2). In contrast, MADR2 phosphorylation in situ hybridization mapping two gene-specific P1-
derived artificial chromosome clones (66i18 and 201n19)was substantially increased in cells cotransfected with
activated TbR I. Tryptic phosphopeptides from this sam- to 18q21 (S. W. S., unpublished data).
The observation that MADR2 mapped to chromosomeple yielded one major novel phosphopeptide, indicating
that phosphorylation is specific (M. Macias-Silva, L. A., 18q21 prompted us to determine its relative location
with respect toDPC4 and DCC, which also map to 18q21and J. L. W., unpublished data). Immunoblotting with
antiflag antibody of total cell lysates prepared in parallel (Hahn et al., 1996a) and have been shown to be fre-
quently deleted in pancreatic cancer (Hahn et al., 1996a,confirmed that approximately equivalent amounts of
MADR2 protein were examined (Figure 2). In a parallel 1996b) and colon cancer (Fearon et al., 1990; Vogelstein
et al., 1988), respectively. Accordingly, gene-specificanalysis of MADR1, increased phosphorylation was de-
tected only in cells cotransfected with constitutively ac- sequence-tagged sites (STSs) for DPC4 and DCC were
tested against the RH panel and all of the YAC clonestive ALK-3, as shown previously (data not shown; Hood-
less et al., 1996). from the WC18.5 contig. Using the previously published
YAC and RH map (Hudson et al., 1995) as a framework,To determine whether MADR2 phosphorylation was
regulated in a TGFb–dependent manner, we stably we could establish the following order: 18cen-MADR2-
DPC4-DCC-18qter (Figure 3). Both the YAC and RH datatransfected mink lung (Mv1Lu) epithelial cell lines with
FlagMADR2 under thecontrol of an inducible-metallothi- for the genes were in complete agreement. However,
the precise physical distance separating the genes wasonein promoter (Wrana et al., 1992). Mv1Lu epithelial
cells express both type I and type II receptors and are difficult to establish, since the map was based only on
STS content and because two gaps are present withinTGFb–sensitive. Several independent pools of cells ex-
pressing FlagMADR2 in a zinc-inducible manner were the YAC contig (Figure 3). Nevertheless, it was evident
that MADR2 mapped to the same cytogenetic band asgenerated, and the regulation of MADR2 phosphoryla-
tion in response to TGFb was examined in two pools. DPC4 and DCC and within close enough physical prox-
imity to suggest that it may also be frequently deletedAnalysis of MADR2 immunoprecipitated from [32P]phos-
phate-labeled cells that were untreated or treated with in tumors demonstrating LOH of 18q21.
Cell
546
Figure 3. The Physical Position of MADR2 at Chromosome 18q21
(Top to bottom) The position of MADR2, DPC4, and DCC within the context of the Whitehead Institute RH framework map (Hudson et al.,
1995) and the Genethon genetic linkage map is shown. MADR2, DPC4, and DCC are shown to map 9.32 cR, 10.31 cR, and 8.0 cR from
D18S460, D18S984, and WI-5257, respectively. The RH data was used to estimate the location of the genes, but their exact position with
respect to other markers was determined by YAC contig analysis. An STS contig map of a subset of YAC clones from the Whitehead
Institute–MIT Center for Genome Research contig WC18.5 (Hudson et al., 1995) allowed more precise ordering of the three genes and
surrounding markers. Closed circles on the YACs indicate the DNA markers we determined to be positive, while open circles represent markers
that were expected to be positive but were not. The two vertical broken lines delineate gaps in the YAC contig. YACs 766a1, 785d4, 786c3,
787f7, 787g3, 887e9, 896f12, 908a7, 938b5, 940e10, and 955f10 are chimeric. DNA marker DCC. PCR2.1/2.2 and DCC. PCR36.1/36.2 represent
the 59- and 39-end of DCC, respectively. The STS content data of the YACs suggests the orientation of DCC, which spans approximately 1.3
Mb of DNA (Cho et al., 1994) along the chromosome, to be 18cen-59-DCC-39-18qter. MADR2 has been shown to map to 18q21 in this study,
DPC4 maps to 18q21.1 (Hahn et al., 1996a), and DCC maps to 18q21.3 (GenBank Database).
MADR2 Is Mutated in Colorectal Carcinoma MADR2 was found to have wild-type sequence, indicat-
ing that these mutations were acquired as somaticThe localization of MADR2 to 18q21 led us to investigate
whether mutations in this gene might play a role in the events. These latter studies also served to demonstrate
that MADR2 is expressed in normal human colorectaldevelopment of some forms of cancer. To explore this
possibility, we examined a variety of human tumors for tissue. We also examined SSCP band intensities. Com-
parison of mutant and wild-type alleles in each tumormutations in MADR2 using single-strand conformation
polymorphism (SSCP) analysis of cDNA. We focused on sample showed that tumors 357 and 369 had little or
no wild-type message, suggesting LOH at this locus. Tothe MH1 and MH2 domains of MADR2, which display
the highest degree of similarity among members of the date, we have not found evidence for germline mutations
of MADR2 in a panel of lymphoblastoid lines generatedMAD family. Furthermore, it is within the MH2 domain
that all of the identified mutations in DPC4 reside (Hahn from 15 patients who had a strong family history of
colorectal tumors or who presented with colorectal can-et al., 1996a). Our initial screen of 101 axillary node–
negative breast carcinomas and 76 sarcomas (which cer at a young age. Together, these data show that
mutations in MADR2 are specifically associated withincluded 35 osteosarcomas) did not reveal any muta-
tions, with the exception of a single benign polymor- sporadic colorectal carcinoma and suggest that MADR2
is a candidate tumor suppressor at 18q21.phism at an arginine residue inone breast cancer sample
(nucleotide 1245: A→G). However, in a screen of 66
sporadic colon carcinomas, we identified four tumors
that had missense mutations in MADR2 (6%). In none MADR2 Containing Missense Mutations
Are Not Regulated by TGFbof the samples did we detect any other neutral polymor-
phisms. For three of the mutations, alterations occurred Mutation of a conserved residue within the MH2 domain
of MADR1 has been shown to disrupt regulation by thein highly conserved residues within the MH2 domain
and involved two nonconservative (P445H and L440R) BMP2 signaling pathway and correlates with the loss of
functional protein (Hoodless et al., 1996; Savage et al.,and one conservative (D450E) change (Figure 4; Table
1). The fourth missense mutation mapped to the MH1 1996; Sekelsky et al., 1995). To determine the potential
consequences of the missense mutations we identifieddomain and resulted in the alteration of a highly con-
served arginine residue to a cysteine (R133C; Figure 4; in the MH2 domain of MADR2, we investigated the regu-
lation of the mutant proteins by the TGFb signaling path-Table 1). In the three cases in which adjacent normal
colorectal tissue was available (213, 357, and 348), way. To test this, we introduced the mutations L440R,
MADR2 in Colorectal Carcinoma
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Figure 5. Analysis of TGFb–Regulated Phosphorylation of MADR2
Harboring Missense Mutations
COS-1 cells were transiently transfected with empty vector (2),
FlagMADR2 wild-type (WT) alone, or FlagMADR2 wild-type or mu-
tated (213, 357, or 369) together with wild-type (WT) or constitutively
active (A) TbRI. Transfected cells were labeled with [32P]phosphate,
and FlagMADR2 was purified from cell lysates by immunoprecipita-
tion using anti-Flag antibodies and was analyzed by SDS–PAGE and
autoradiography (32PO4). Total MADR2 protein was determined by
immunoblotting of total cell lysates using anti-Flag monoclonal anti-
body (a-Flag blot). The migration of MADR2 is indicated on the left.
Note that the apparent change in migration on the Western blot is
a gel artifact and is not reproducible.
Figure 4. MADR2 Mutations Present in Colorectal Tumor Samples
unable to detect any stable protein expression (Figure(A) SSCP analysis of MADR2. Mutation 348 is from region 1, and
5). This may indicate that the L440R mutation disturbsmutations 213,357, 369 arefrom region3. Sample 213 is represented
by T (tumor) and N (normal colon tissue). In each case, the mutant the stability of the nascent protein or interferes with
is followed by cases with wild-type SSCP banding patterns that translation of the mRNA. These results provide strong
were run in adjacent lanes. evidence that the missense mutations in MADR2, identi-
(B) Summary of predicted amino acid alterations resulting from fied in colorectal carcinomas, lead to disruption of TGFb
MADR2 mutations. The amino acid sequence of MADR2, from amino
regulation and may lead to the concomitant loss of TGFbacid 130 to 137 of the MH1 domain and from amino acid 439 to 452
sensitivity in the target cells.of the MH2 domain, are aligned with the corresponding regions in
MADR1 and DPC-4. Conserved sequences are highlighted (solid
box). The location of the missense mutations and the predicted MADR2 Mutants Are Biologically Inactive in Xenopus
amino acid changes are indicated. Mesoderm Induction Assays
Xenopus blastula stage ectoderm can differentiate into
mesodermal tissues in response to particular membersP445H, and D450E into wild-type FlagMADR2 and ex-
pressed the protein in COS-1 cells together with either of the TGFb superfamily (reviewed by Kessler and Mel-
ton, 1994; Wall and Hogan, 1994). For example, BMPswild-type or constitutively active TbRI. Relative phos-
phorylation levels were assessed by immunoprecipita- induce ventral mesoderm such as blood, whereas ac-
tivin induces dorsal types of mesoderm such as muscletion of MADR2 protein from [32P]phosphate-labeled cells
and quantitating protein levels by Western blotting of and notochord. Similar to the common biological re-
sponses observed for activin and TGFb in mammalianwhole-cell lysates. When wild-type MADR2 was coex-
pressed with activated TbRI, typical elevations in phos- cells (Ca´rcamo et al., 1994), TGFb can also induce dorsal
mesoderm in caps ectopically expressing TGFb type IIphorylation of MADR2 were observed (Figure 5). In con-
trast, two of the MADR2 mutants, 213 and 357 (P445H receptor (Bhushan et al., 1994). Further, overexpression
of a Xenopus homolog of TbRI that is 98% identical toand D450E, respectively), showed no alterations in rela-
tive phosphorylation upon coexpression with activated TbRI in the kinase domain similarly results in formation
of dorsal mesoderm (Mahony and Gurdon, 1995). Inter-receptors. Thus, both the nonconservative P445H and
the conservative D450E mutations disrupt the regulation estingly, overexpression of the Xenopus MAD–related
proteins, XMad1 and XMad2, in the ectoderm mimicsof MADR2 phosphorylation. In several attempts to ex-
press the 369 mutant (L440R) in COS cells, we were these effects. Thus, XMad1 (or XMad) induces ventral
Table 1. Missense Mutations in MADR2
Normal
Sample Codon Mutation Amino Acid Change Tissue Effect
213 445 CCT→CAT Pro→His wild-type no phosphorylation
369 440 CTT→CGT Leu→Arg wild-type unstable protein
357 450 GAC→GAG Asp→Glu N/A no phosphorylation
348 133 CGC→TGC Arg→Cys wild-type not done
Cell
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mesoderm, while XMad2, like TGFb or activin, yields
dorsal types of mesoderm (Graff et al., 1996; Thomsen,
1996).
Since the protein sequence of human MADR2 is 98%
identical to XMad2 (data not shown), we examined the
effect of MADR2 expression in Xenopus embryos.
MADR2 could induce mesoderm and trigger morphoge-
netic movements in a fashion similar to that of XMad2
(Figure 6). Expression of MADR2 from microinjected
mRNA caused Xenopus ectoderm explants, or animal
caps, to elongate (Figure 6A), as observed when TbRII-
expressing caps are treated with TGFb (Bhushan et al.,
1994). These shape changes are considered to reflect
the cellular movements that normally occur in the dorsal
embryonic mesoderm during gastrula and neurula
stages. MADR2 could also trigger ectopic gastrulation
movements in the ectoderm of intact embryos (Figure
6A) precisely at the time that normal gastrulation move-
ments began on the dorsal side of the embryo in the
Spemann organizer. The MADR2 mutants 213, 357, and
369, however, did not cause animal caps to elongate or
produce ectopic gastrulation movements in embryos,
suggesting that the mutant proteins are functionally in-
active.
We also tested wild-type and mutant MADR2 proteins
for their capacity to induce mesoderm in animal caps.
Wild-type MADR2 induced strong expression of the gen-
eral mesodermal marker gene, brachyury (Xbra; Smith
et al., 1991), but the mutants did not (Figure 6B). The
lack of activity observed for the MADR2 mutants was
not due to a lack of protein expression. Western blot
analysis of MADR2 protein expression in injected animal
caps showed that wild-type and mutant MADR2 were
produced at nearly equal levels, except for 369, which
was expressed at lower levels consistent with its appar-
ent instability in mammalian tissue culture cells. These
observations demonstrate that the mutations detected
in colorectal tumors disrupt regulation by the TGFb sig-
Figure 6. Induction of Morphogenetic Movements and Mesoderm
naling pathway and yield biologically inactive MADR2by Wild-Type But Not Mutant MADR2 Proteins
protein.
(A) Animal caps cut from embryos injected with wild-type MADR2
caps elongate as they undergo morphogenetic movements associ-
ated with mesoderm differentiation, but control caps and ones ex- Discussion
pressing mutant MADR2 proteins do not. Intact embryos expressing
mutant and wild-type MADR2 in the animal pole were also scored
MAD and MAD–related proteins are a novel family offor ectopic sites of gastrulation. A representative control embryo is
proteins that function downstream of serine/threonineshown, and it is indistinguishable from embryos that expressed the
kinase receptors to transduce signals for members ofmutant forms of MADR2. An embryo expressing wild-type MADR2
shows an additional invagination furrow (white arrow) whose time the TGFb superfamily (reviewed by Massague´, 1996;
of appearance coincided with the formation of the dorsal lip of the Wrana and Attisano, 1996). In this study, we report the
Spemann organizer, the normal site of gastrulation initiation. The characterization of MADR2 as an intracellular compo-
normal gastrulation furrow (black arrow) of the embryo pictured here nent of the TGFb signaling pathway. We show that it
is displaced from its usual more vegetal position, because of the
maps to a tumor suppressor locus at 18q21 and thataction of the ectopic furrow. All wild-type MADR2–injected embryos
the gene is mutated in approximately 6% of sporadicdisplayed the phenotype shown (for all sets of embryos, n > 12).
The embryos analyzed were siblings of those used in the animal colorectal carcinomas. We demonstrate that these mu-
cap assays in (B), all of which expressed MADR2 proteins. tations disrupt either the regulation of MADR2 by TGFb
(B) RT–PCR analysis on animal caps injected with wild-type and
mutated MADR2 mRNAs show that only wild-type, and not mutated,
MADR2 induces mesoderm as scored by the expression of brachy-
ury, a general mesoderm marker at early to mid-gastrulation. Caps body is shown in the lower panel. The Western blot confirms that
were injected with control (C; pGEM vector transcripts) and wild- the various MADR2 proteins were synthesized in each set of caps,
type or mutant MADR2 mRNAs as indicated. EF1-a expression was although mutant 369 displayed a lower level of expression. Animal
scored as a general marker for RNA recovery. The emb RT plus and caps (10) were pooled for each sample analyzed by Western blot,
minus lanes are positive and negative controls, using total embry- and two cap equivalents were loaded per lane. Approximately 24
onic RNA that was (1) or was not (2) reverse-transcribed. A Western caps were cut at late blastula (stage 8); at mid-gastrula (stage 12),
blot of animal cap proteins stained with an anti-Flag anti- half were harvested for RT–PCR and half for protein analysis.
MADR2 in Colorectal Carcinoma
549
signaling pathways or the stable expression of the pro- not determined whether this is due to a defect in transla-
tion or stability of the protein product, this mutation maytein. Furthermore, using a Xenopus model system, we
showthat these mutations lead to inactivation of MADR2 result in loss of MADR2 expression in target cells. In
contrast, two of the mutations in the MH2 domain char-protein function.
acterized from tumors disrupt the regulation of MADR2
phosphorylation by TGFb signaling pathways. StudiesMADR2 Functions in the TGFb Signaling Pathway
on MADR1 have previously identified a mutation withinGenetic studies in Drosophila and C. elegans have dem-
the MH2 domain that blocks phosphorylation by theonstrated that MADs are required for signaling by recep-
BMP signaling pathways (Hoodless et al., 1996). Thistors for the TGFb superfamily (Hoodless et al., 1996;
particular mutation generates null phenotypes in Dro-Newfeld et al., 1996; Savage et al., 1996; Wiersdorff et
sophila or C. elegans, providing evidence that theseal., 1996). MADR1 has been shown previously to be
types of mutations yield nonfunctional protein productsspecifically regulated by BMPs (Hoodless et al., 1996),
(Savage et al., 1996; Sekelsky et al., 1995). We alsoand in this study, we show that MADR2 is regulated by
observed similar inactivation of MADR2 protein functionTGFb signaling pathways. These results demonstrate
in Xenopus embryonic assays. Wild-type MADR2 in-that at least in the case of MADR1 and MADR2, these
duces mesoderm and morphogenetic movements simi-molecules lie in specific serine/threonine kinase recep-
lar to that seen with Xenopus Mad2, and these activitiestor signaling pathways. Studies in Xenopus further high-
are abolished for mutant MADR2 proteins. These find-light this specificity, since overexpression of specific
ings suggest that alterations within the MH2 domain ofMADs can recapitulate the biological response normally
MADRs can disrupt regulation of phosphorylation andinduced by activation of the upstream receptors. Hence,
indicate that phosphorylation is important for MADRXMad1 signals BMP–like responses, while XMad2/
function.MADR2 signals TGFb/activin–like responses (this study;
Graff et al., 1996; Thomsen, 1996). Thus, MADs play a
central role in determining cellular responses to TGFb– Disruption of MADR2 and TGFb Signaling
like factors, and mutations that disrupt MADR2 function in Tumorigenesis
are likely to result in specific defects in TGFb signaling. Regardless of the mechanism, the MADR2 mutations
we have identified in colorectal carcinoma yield non-
functional protein. Thus, these mutations should leadMADR2 Is a Tumor Suppressor
to a similar loss of activity in the developing tumors.Tumor suppressor genes are often inactivated when one
This might lead to a disruption of TGFb signaling andallele acquires a somatic mutation and the second allele
thereby result in a loss of TGFb sensitivity in the targetis lost, typically through deletion (Cavenee et al., 1983).
cells. Since TGFb is a potent antiproliferative factor forLOH at 18q21 has been identified in numerous human
a broad range of epithelial cells, mutations in signalingcancers (Vogelstein et al., 1988; Yamaguchi et al., 1992).
components of this pathway may thus allow tumor cellsWe mapped MADR2 to this region of thehuman genome,
to escape this regulation. This would clearly give neo-raising the possibility that MADR2 acts as a tumor sup-
plastic clones a growth advantage in the tissue. Thus,pressor. Our random screen of 76 sarcomas, 101 breast
loss of MADR2 function may make a major contributioncarcinomas, and 66 sporadic colorectal carcinomas
to the development of cancer.identified four mutations specific to colon carcinoma,
of which at least three were acquired somatically. In
two of the samples, we could clearly detect wild-type 18q21 Is a Locus for Multiple Tumor
MADR2. Since this may bedue to the presence of normal Suppressor Genes
tissue in the specimen or to tumor heterogeneity, this LOH at 18q21 is frequently detected in many human
precluded a determination of potential LOH in these cancers (Fearon et al., 1990; Vogelstein et al., 1988;
individuals. Nonetheless, in two of our cases, there was Yamaguchi et al., 1992). Interestingly, DPC4, another
very low expression or loss of the normal allele sugges- MAD–related gene, has also been mapped to 18q21 in
tive of an LOH of MADR2. Together with the observation close proximity to MADR2 and has been identified as a
that these mutations are inactivating, these results pro- candidate tumor suppressor in pancreatic carcinoma
vide strong evidence that MADR2 is a tumor suppressor (Hahn et al., 1996a). A similar situation exists for adeno-
gene in sporadic colorectal cancers. Recently, Riggins matous polyposis coli and mutated-in-colon cancer on
et al. (1996) also reported the presence of a genetic chromosome 5q21 (Joslyn et al., 1991; Kinzler et al.,
alteration in a colorectal tumor of a gene, JV18-1, which 1991). Adenomatous polyposis coli mutations contrib-
is likely to be the same as MADR2 described here. ute to the development of sporadic and familial colo-
rectal cancers; and both adenomatous polyposis coli
and mutated-in-colon cancer are located in close physi-Missense Mutations in MADR2 Are
Functionally Disrupted cal proximity, share significant sequence homology with
coiled-coil class proteins and are frequently deletedOur analyses of the regulation of MADR2 by TGFb sig-
naling pathways demonstrate that the somatic muta- concurrently inmany different cancers. It is interesting to
speculate on the functional relationship between DPC4tions we have characterized can lead to two distinct
defects. Characterization of the nonconservative L440R and MADR2. DPC4 may function downstream of a differ-
ent TGFb superfamily member whose function is impor-mutation revealed that this change results in a defect in
stable expression of MADR2 protein both in mammalian tant in controlling the growth of pancreatic cells. How-
ever, it is also possible that DPC4 might also functionepithelial cells and in Xenopus embryos. While we have
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forw. 59-ACCAATCAAGTCCCATGAAA-39; rev. 59 TGATCGAGACCTin the TGFb signaling pathway, as suggested recently
CAAGTGCTG-39; DPC4. UTR: forw. 59 ATTGAAATTCACTTACACCfor themultiple sma genes in BMP signaling in C. elegans
GGG-39; rev. 59-AGCCATGCCTGACAAGTTCT-39. The primers DCC.(Savage et al., 1996). If the latter is the case, it raises
PCR2.1/2.2 and DCC. PCR36.1/36.2, which are specific for the most
the possibility that MADR2 and DPC4 together may 59 and 39 exons, respectively, of DCC, are described in the GenBank
function in a cooperative way and that mutations in Database. Information on all of the other primers shown in Figure
3 is available from the MIT Genome Center (http://www-genome.either gene would allow cells to escape from TGFb sen-
wi.mit.edu/) or is described by Hahn et al. (1996b). The conditionssitivity. Thus, both MADR2 and DPC4 could be impli-
of PCR for all mapping experiments were: initial denaturation for 2cated as tumor suppressor genes in a variety of tumors
min at 948C, followed by 35 cycles of denaturing for 40 s at 948C,of the gastrointestinal tract.
annealing for 40 s at 558C, and extension for 40 s at 728C, 35 cycles.
RH mapping experiments were carried out in duplicate using the
Experimental Procedures Genebridge 4 panel (Walter et al., 1994; purchased from Research
Genetics). The Whitehead Institute–MIT Center for Genome Re-
Construction of Expression Vectors search RH server was used to order the new STSs relative to frame-
Several clones displaying similarity to MADR1 (clone ID numbers work markers. All of the protocols used for YAC manipulations have
136422, 145032, and 138604) were identified from the expressed been described previously (Scherer and Tsui, 1991). MADR2 de-
sequence database (I.M.A.G.E.; Lennon et al., 1996). A pair of clones tected YACs C739a3, C749d11, C887e9, C929d7, and C940e10;
(ID numbers 136422 and 145032) were obtained and sequenced DPC4 was positive for C747a6, C786c3, C917c8, C945b11, and
(SequenaseTM 2.0 Kit, US Biochemicals). Both encoded MADR2 from C957b11; DCC. PCR2.1/2.2 detected 746h3, 787f7, 787g3, 818e6,
nucleotides 240 to 1551. A single clone (ID 138604) appeared to 821b7, 838b4, 849d6, 945b11, and 956a9; and DCC. PCR36.1/36.2
encode a stop codon. To obtain a full-length cDNA for MADR2, identified 782g1, 787f7, 790d12, 821b7, 830g12, 838b4, 905e8,
sense and antisense primers containing convenient restriction sites 945b11, and 966e5.
for subcloning were designed based on sequence obtained from
the expressed sequence database clones. To allow introduction of Mutational Analysis
an epitope tag into the amino-terminus of MADR2, the start methio- cDNA was synthesized from tissue total RNA using Murine Moloney
nine in the sense primerwas replaced with a SalI site and a glutamine leukemia virus reverse transcriptase (Gibco–BRL) and random hex-
residue to allow direct subcloning into pCMV5-Flag (Hoodless et amers. Each SSCP PCR reaction was carried out in a 20 ml reaction
al., 1996). PCR was performed with a human kidney cDNA library composed of 1 3 PCR buffer (10 mM Tris–HCl [pH 8.3], 50 mM KCl,
as template (Clontech, pGAD424 library). To obtain the full cDNA 0.01% gelatin), 1.6 mM MgCl2, 30 mM each dNTPs, 9 pmol of each
coding sequence, two PCR–generated constructs were completely forward and reverse primer, cDNA made from 25 ng of RNA, 1.5
sequenced. To generate FlagMADR2 harboring mutations, a frag- mCi [33P]-dATP (2000 Ci/mmol, NEN-DuPont), and 1 U of AmpliTaq
ment of MADR2 was amplified by PCR using cDNA prepared from DNA polymerase (Perkin-Elmer). Regions 1 (nucleotides 279–542),
colorectal carcinoma RNA samples as template. The amplified re- 2 (nucleotides 778–1014), 3 (nucleotides 1182–1430), and 4 (nucleo-
gion was subcloned into the full-length FlagMADR2 in pCMV5 and tides 953–1245) were amplified with the following primers: Region
the presence of the missense mutations confirmed by sequencing. 1: 59-AGATCAGTGGGATACAACAGG-39 and 59-GGCACTAATACTG
For the generation of stable transfectants, FlagMADR2 was sub- GAGGCAA-39 (264 bp); Region 2: 59-AGCTTGGATTTACAGCC
cloned into pMEP4 (Invitrogen) behind a metallothionein-inducible AGT-39 and 59-TAAGCGCACTCCTCTTCCTA-39 (237 bp); Region 3:
promoter using convenient sites in the vector polylinker (Wrana et 59-GGCTCAGTCTGTTAATCAGG-39 and 59-TTCCATGGGACTTGAT
al., 1992). TGGT-39 (249 bp); Region 4: 59-TGTTAACCGAAATGCCACGG-39 and
59-TCTTATGGTGCACATTCTAGT-39 (293 bp). Regions 1 and 2 were
Cell Lines and Transfections amplified simultaneously in the same reaction tube. Cycling condi-
COS-1 cells were maintained and transfected using the diethylami- tions involved 35 cycles at 948C for 15 s, 558C for 15 s, and 728C
noethyl-dextran as described (Hoodless et al., 1996). The Mv1Lu for 20 s, using the 9600 Thermocycler (Perkin-Elmer). PCR product
mink lung cells (CCL-64) expressing FlagMADR2 in pMEP4 (In- was mixed with 2 vol of denaturing dye (95% formamide, 20 mM
vitrogen) were generated by transfection with lipofectin (Gibco/BRL) EDTA, 0.05% Bromophenol Blue, and 0.05% Xylene Cyanol FF),
as described previously (Wrana et al., 1992). Pools of cell colonies heat-denatured, and loaded on an SSCP gel (8% acrylamide:
were maintained in the continuous presence of hygromycin. Flag- bis-acrylamide [40:1], 0.5 3 Tris–borate–EDTA, and 10% glycerol).
MADR2 expression was induced by the overnight incubation of cells Electrophoresis was carried out at 168C using a StrataTherm Cold
in medium containing 0.2% serum and 50 mM ZnCl2. temperature-controlled apparatus (Stratagene). Mutations were
confirmed by direct sequencing of asymmetric PCR products.
Immunoprecipitations and Immunoblotting
Stably or transiently transfected cells were labeled for 2 hr with Xenopus Embryonic Assays
[32P]phosphate as described previously (Attisano et al., 1996; The cDNAs for MADR2 and its mutant forms were subcloned into
Wrana et al., 1994). For stable cell lines, Zn21-induced monolayers the CS21 vector (Rupp et al., 1994), and plasmids were linearized
were incubated in the presence or absence of 100 pM TGFb (R with NotI prior to SP6 transcriptionof capped synthetic mRNA (using
and D Systems) in the last 15 min of the phosphate labeling. Cell the mMessage Machine kit, Ambion Inc.). Transcripts from a linear-
lysates were subjected to immunoprecipitation with anti-Flag M2 ized vector (pGEM 7) served as a negative control for mRNA injec-
monoclonal antibody (IBI, Eastman Kodak), followed by adsorption tion. Each mRNA (1.0 ng) was injected into the animal pole of a two-
to protein G–sepharose (Pharmacia). Immunoprecipitates were cell blastula (0.5 ng per blastomere), and animal caps were excised
washed, separated by SDS–polyacrylamide gel electrophoresis at blastula stage 8 and cultured in vitro, or the embryos were allowed
(SDS–PAGE), and visualized by autoradiography. For determination to develop intact to assay ectopic gastrulation movements. Proteins
of MADR2 protein levels, lysates were prepared from cells treated for Western blots were prepared by lysing animal caps (10 caps per
in parallel with those subjected to in vivo phosphate labeling. Pro- 100 ml) directly in 2 3 Laemmli gel loading buffer. RNAwas prepared
teins from cell lysates wereseparated by SDS–PAGE and transferred from animal caps and reverse transcriptase–PCR (RT–PCR) per-
to nitrocellulose membranes. FlagMADR1 was detected using anti- formed as described (Thomsen, 1996; Wilson and Melton, 1994)
FLAG M2 antibody (1:3000 dilution) and chemiluminesence as rec- using a 25 ml reaction volume. A fraction (one-half) of a cap or 0.2
ommended by the manufacturer (ECL Kit, Amersham). embryo equivalents were analyzed by RT–PCR, using 17 cycles of
amplification for Ef1-a and 24 cycles for XBra. A fraction (one-fifth)
of each sample was loaded on a 6% PAGE (0.5 3 Tris–borate–EDTA)RH and YAC Contig Mapping
The following PCR primers specific for the 39-UTR of MADR2 and gel. Film (Kodak XAR) was exposed for 3 hr to detect Ef1-a and the
embryo RT plus and minus lanes of Xbra. Xbra signals from animalDPC4 were designed using the Primer Version 3.0 program
(Whitehead Institute–MIT Center for Genome Research): MADR2: caps were exposed for 6 hr.
MADR2 in Colorectal Carcinoma
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